Skip to main content


Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Dynamic tumor modeling of the dose–response relationship for everolimus in metastatic renal cell carcinoma using data from the phase 3 RECORD-1 trial

  • Andrew Stein1Email author,
  • Wenping Wang2,
  • Alison A Carter3,
  • Ovidiu Chiparus4,
  • Norbert Hollaender5,
  • Hyewon Kim6,
  • Robert J Motzer7 and
  • Celine Sarr8
BMC Cancer201212:311

DOI: 10.1186/1471-2407-12-311

Received: 6 March 2012

Accepted: 21 June 2012

Published: 23 July 2012

Back to article

Open Peer Review reports

Pre-publication versions of this article and author comments to reviewers are available by contacting

Original Submission
6 Mar 2012 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
23 Mar 2012 Reviewed Reviewer Report - Lai San Tham
30 Mar 2012 Reviewed Reviewer Report - Yaning Wang
8 May 2012 Author responded Author comments - Andrew Stein
Resubmission - Version 3
8 May 2012 Submitted Manuscript version 3
18 May 2012 Reviewed Reviewer Report - Lai San Tham
Resubmission - Version 4
Submitted Manuscript version 4
21 Jun 2012 Editorially accepted
23 Jul 2012 Article published 10.1186/1471-2407-12-311

How does Open Peer Review work?

Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article.. All previous versions of the manuscript and all author responses to the reviewers are also available.

You can find further information about the peer review system here.

Authors’ Affiliations

Modeling & Simulation, Novartis Institutes for Biomedical Research
Novartis Pharmaceuticals Corporation
Novartis Pharmaceuticals Corporation
Novartis Pharmaceuticals Corporation
Novartis Pharma AG
Department of Experimental and Clinical Pharmacology, University of Minnesota
Department of Medicine, Genitourinary Oncology Service, Memorial Sloan-Kettering Cancer Center
Novartis Pharmaceuticals Corporation